Biogen CapEx increased by 16.6% to $51.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 38.0%, from $37.10M to $51.20M. Over 4 years (FY 2021 to FY 2025), CapEx shows a downward trend with a -12.1% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $71.90M | $42.00M | $51.60M | $57.90M | $36.90M | $59.10M | $86.40M | $66.60M | $71.00M | $74.20M | $65.20M | $45.90M | $33.50M | $35.00M | $39.30M | $37.10M | $26.60M | $46.20M | $43.90M | $51.20M |
| QoQ Change | — | -41.6% | +22.9% | +12.2% | -36.3% | +60.2% | +46.2% | -22.9% | +6.6% | +4.5% | -12.1% | -29.6% | -27.0% | +4.5% | +12.3% | -5.6% | -28.3% | +73.7% | -5.0% | +16.6% |
| YoY Change | — | — | — | — | -48.7% | +40.7% | +67.4% | +15.0% | +92.4% | +25.5% | -24.5% | -31.1% | -52.8% | -52.8% | -39.7% | -19.2% | -20.6% | +32.0% | +11.7% | +38.0% |